Call the KY House Representatives TODAY as tell them to REMOVE section 25(d) in House Bill 333.
HB-333 - Kentucky
Kentucky’s HB 333 - Let's Address the Hidden Language
By: Alli Cloyd
Hidden in plain sight is the latest way to make the CBD market a monopoly for GW Pharmaceuticals. Introduced by Rep. Kim Moser and R-Taylor Mill. HB 333 of Kentucky is a Bill designed to combat the lethal drug Fentanyl, commonly found in Heroin.
However, when read closer, this Bill would make it illegal to consume any part of the hemp plant WITHOUT A PRESCRIPTION.
This is a huge threat to the hemp market in Kentucky. This is not the first we are hearing of this type of threat to the cannabis industry. “GW Pharmaceuticals has been developing a CBD-based drug called Epidiolex for years and, now that the drug is in Phase III trials, it’s predicted to receive FDA approval soon.
Presumably in anticipation of its approval, Greenwich Biosciences has worked to introduce bills in South Dakota and Nebraska that would essentially require all CBD products sold in the state to have been approved by the FDA. This would lead to an immediate GW monopoly on the CBD marketplace in those states, as Epidiolex will be the only such product with FDA approval.”
Highlighted below is part of the Bill that would be detrimental to the cannabis and hemp industry.
(25)[(22)] "Marijuana" means all parts of the plant Cannabis sp., whether growing or 13 not; the seeds thereof; the resin extracted from any part of the plant; and every 14 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its 15 seeds or resin or any compound, mixture, or preparation which contains any 16 quantity of these substances. The term "marijuana" does not include: 17 (a) Industrial hemp as defined in KRS 260.850; 18 (b) The substance cannabidiol, when transferred, dispensed, or administered 19 pursuant to the written order of a physician practicing at a hospital or 20 associated clinic affiliated with a Kentucky public university having a college 21 or school of medicine;[ or] 22 (c) For persons participating in a clinical trial or in an expanded access program, 23 a drug or substance approved for the use of those participants by the United 24 States Food and Drug Administration; or 25 (d) A cannabidiol product approved as a prescription medication by the United 26 States Food and Drug Administration;
Let's tell the KY House of Representatives NOW that this bill must be stopped. Just passed 3rd reading in the Senate, next is the House.